Literature DB >> 33444355

The temporospatial epidemiology of rheumatic heart disease in Far North Queensland, tropical Australia 1997-2017; impact of socioeconomic status on disease burden, severity and access to care.

Katherine Kang1, Ken W T Chau1, Erin Howell2, Mellise Anderson2, Simon Smith1, Tania J Davis3, Greg Starmer3, Josh Hanson1,4.   

Abstract

BACKGROUND: The incidence of rheumatic heart disease (RHD) among Indigenous Australians remains one of the highest in the world. Many studies have highlighted the relationship between the social determinants of health and RHD, but few have used registry data to link socioeconomic disadvantage to the delivery of patient care and long-term outcomes.
METHODS: A retrospective study of individuals living with RHD in Far North Queensland (FNQ), Australia between 1997 and 2017. Patients were identified using the Queensland state RHD register. The Socio-Economic Indexes for Areas (SEIFA) Score-a measure of socioeconomic disadvantage-was correlated with RHD prevalence, disease severity and measures of RHD care.
RESULTS: Of the 686 individuals, 622 (90.7%) were Indigenous Australians. RHD incidence increased in the region from 4.7/100,000/year in 1997 to 49.4/100,000/year in 2017 (p<0.001). In 2017, the prevalence of RHD was 12/1000 in the Indigenous population and 2/1000 in the non-Indigenous population (p<0.001). There was an inverse correlation between an area's SEIFA score and its RHD prevalence (rho = -0.77, p = 0.005). 249 (36.2%) individuals in the cohort had 593 RHD-related hospitalisations; the number of RHD-related hospitalisations increased during the study period (p<0.001). In 2017, 293 (42.7%) patients met criteria for secondary prophylaxis, but only 73 (24.9%) had good adherence. Overall, 119/686 (17.3%) required valve surgery; the number of individuals having surgery increased over the study period (p = 0.02). During the study 39/686 (5.7%) died. Non-Indigenous patients were more likely to die than Indigenous patients (9/64 (14%) versus 30/622 (5%), p = 0.002), but Indigenous patients died at a younger age (median (IQR): 52 (35-67) versus 73 (62-77) p = 0.013). RHD-related deaths occurred at a younger age in Indigenous individuals than non-Indigenous individuals (median (IQR) age: 29 (12-58) versus 77 (64-78), p = 0.007).
CONCLUSIONS: The incidence of RHD, RHD-related hospitalisations and RHD-related surgery continues to rise in FNQ. Whilst this is partly explained by increased disease recognition and improved delivery of care, the burden of RHD remains unacceptably high and is disproportionately borne by the socioeconomically disadvantaged Indigenous population.

Entities:  

Mesh:

Year:  2021        PMID: 33444355      PMCID: PMC7840049          DOI: 10.1371/journal.pntd.0008990

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  42 in total

1.  HTLV-1 is rare in Far North Queensland despite a significant burden of classically associated diseases.

Authors:  Simon Smith; Darren Russell; Peter Horne; Josh Hanson
Journal:  Pathology       Date:  2018-11-28       Impact factor: 5.306

2.  Low positive predictive value of International Classification of Diseases, 10th Revision codes in relation to rheumatic heart disease: a challenge for global surveillance.

Authors:  Judith M Katzenellenbogen; Lee Nedkoff; Jeffrey Cannon; Deborah Kruger; Filippa Pretty; Jonathan R Carapetis; Karen E Dempsey; Jess De Dassel; Mellise Anderson; Nicholas de Klerk; Joseph Hung
Journal:  Intern Med J       Date:  2019-03       Impact factor: 2.048

3.  Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States.

Authors:  B F Massell; C G Chute; A M Walker; G S Kurland
Journal:  N Engl J Med       Date:  1988-02-04       Impact factor: 91.245

Review 4.  The inequitable burden of group A streptococcal diseases in Indigenous Australians.

Authors:  Philippa J May; Asha C Bowen; Jonathan R Carapetis
Journal:  Med J Aust       Date:  2016-09-05       Impact factor: 7.738

5.  Measuring diagnoses: ICD code accuracy.

Authors:  Kimberly J O'Malley; Karon F Cook; Matt D Price; Kimberly Raiford Wildes; John F Hurdle; Carol M Ashton
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

6.  A Wilcoxon-type test for trend.

Authors:  J Cuzick
Journal:  Stat Med       Date:  1985 Jan-Mar       Impact factor: 2.373

7.  The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture.

Authors:  L Gordis
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

8.  The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease.

Authors:  Anna P Ralph; Sara Noonan; Vicki Wade; Bart J Currie
Journal:  Med J Aust       Date:  2020-11-15       Impact factor: 7.738

Review 9.  The Relationship between Infectious Diseases and Housing Maintenance in Indigenous Australian Households.

Authors:  Shahmir H Ali; Tim Foster; Nina Lansbury Hall
Journal:  Int J Environ Res Public Health       Date:  2018-12-11       Impact factor: 3.390

View more
  3 in total

1.  Examination of the independent contribution of rheumatic heart disease and congestive cardiac failure to the development and outcome of melioidosis in Far North Queensland, tropical Australia.

Authors:  Phoebe Davies; Simon Smith; Rob Wilcox; James D Stewart; Tania J Davis; Kylie McKenna; Josh Hanson
Journal:  PLoS Negl Trop Dis       Date:  2022-07-18

2.  The epidemiology and outcomes of central nervous system infections in Far North Queensland, tropical Australia; 2000-2019.

Authors:  Hannah Gora; Simon Smith; Ian Wilson; Annie Preston-Thomas; Nicole Ramsamy; Josh Hanson
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

3.  Rheumatic Heart Disease Is a Neglected Disease Relative to Its Burden Worldwide: Findings From Global Burden of Disease 2019.

Authors:  Seyyed-Hadi Ghamari; Mohsen Abbasi-Kangevari; Sahar Saeedi Moghaddam; Arya Aminorroaya; Negar Rezaei; Parnian Shobeiri; Zahra Esfahani; Mohammad-Reza Malekpour; Nazila Rezaei; Ali Ghanbari; Mohammad Keykhaei; Mohammadreza Naderian; Bagher Larijani; Mohamad Taghi Majnoon; Farshad Farzadfar; Ali H Mokdad
Journal:  J Am Heart Assoc       Date:  2022-06-22       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.